Fda Is Reviewing Ranbaxys Corrective Strategy On Drugs to The U.s.
“The FDA is working very closely with the firm to ensure that all the Ranbaxy products currently in the U.S. market are safe and effective,” FDA spokesman Christopher Kelly said in an e-mail yesterday. “The next steps will be dependent on the actions identified” in the plan, he said.
U.S. sales of Ranbaxy, Indias biggest drugmaker, fell for two straight quarters after the U.S. Food & Drug Administration on Sept. 16 blocked the import of 30 medicines produced at two of its factories. The FDA decision to block the products in the U.S., the worlds largest drug market, led Ranbaxys stock to plunge 45 percent until Chief Executive Officer Atul Sobti said earlier this week that the company had submitted the plan.
The regulator in February barred Ranbaxy from introducing new generic medicines from one of the two plants. The FDA said Ranbaxy falsified data from the factory in Paonta Sahib, northern India. Drugs from that plant were approved for sale in the U.K. and Australia after a joint audit by regulators, Ranbaxy said March 23.
Ranbaxy, controlled by Tokyo-based Daiichi Sankyo Co., rose 0.4 percent to 262.85 rupees as of 10:31 a.m. in Mumbai trading, while Indias benchmark Sensitive Index gained 1 percent.
Sobti, who replaced Malvinder Singh as CEO under a plan by its parent to turn around the unprofitable company, said Ranbaxy expects the full approval process by the FDA to take months.
The FDA said it received Ranbaxys corrective action plan on May 18.